

## Xeloda® (capecitabine) Prior Authorization Request Form (Page 1 of 2)

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information <small>(required)</small>					
<b>Select the diagnosis below:</b> <input type="checkbox"/> Metastatic breast cancer <input type="checkbox"/> Metastatic colorectal cancer Other: _____ ICD-10 code(s): _____					
<b>For breast cancer, answer the following:</b> Select the intent of therapy below: <input type="checkbox"/> Monotherapy <input type="checkbox"/> Used in combination with docetaxel Has the patient failed prior anthracycline-containing therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Select if the patient is resistant to the following therapies: <input type="checkbox"/> An anthracycline-containing regimen (or for whom further anthracycline therapy is not indicated) <input type="checkbox"/> Paclitaxel Is the patient's creatinine clearance greater than or equal to 30 mL/minute? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For colon cancer, answer the following:</b> Does the patient have a diagnosis of Duke's C colon cancer? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient undergone complete resection of the primary tumor? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient's creatinine clearance greater than or equal to 30 mL/minute? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Reauthorization:</b> <b>If this is a reauthorization request, answer the following questions:</b> Does the patient show evidence of progressive disease while on Xeloda therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient's creatinine clearance greater than or equal to 30 mL/minute? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient experienced severe mucocutaneous reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis)? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a neutrophil count less than 1.5 x 10 <sup>9</sup> /L? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a thrombocyte count less than 100 x 10 <sup>9</sup> /L? <input type="checkbox"/> Yes <input type="checkbox"/> No					



1230 US Highway 11  
Gouverneur, NY 13642  
Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

## Xeloda® (capecitabine) Prior Authorization Request Form (Page 1 of 2)

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.

**Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.**

**Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.**

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): \_\_\_\_\_ Date: \_\_\_\_\_

### PROACT INTERNAL USE ONLY:

#### Clinical Review Decision

Approved, through

Denied (documentation attached, if necessary)

#### Tracking:

1<sup>st</sup> Attempt

2<sup>nd</sup> Attempt

Letter Mailed:

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Xeloda-capecitabine\_Jan\_2018